Preeclampsia diagnostics includes laboratory tests used to detect any abnormalities related to blood pressure during pregnancy that can potentially cause complications in expecting mothers. Preeclampsia diagnostics helps in early detection of the condition by diagnosing signs like high blood pressure and excessive protein levels in urine. Timely diagnosis with the help of preeclampsia diagnostics can help reduce the risks of severity and support proper medical management of the condition.

The global Preeclampsia Diagnostics Market is estimated to be valued at Us$ 1587.53 Mn in 2023 and is expected to exhibit a CAGR Of 5.6% over the forecast period 2023 To 2030, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity

Development of Novel Diagnostic Solutions:

The growing incidences of preeclampsia globally have led to increased focus on developing novel diagnostic solutions for improved detection of the condition. Researchers are working on biomarkers and diagnostic kits that can help diagnose preeclampsia even before the appearance of symptoms. This provides an opportunity for market players to gain significant revenue by investing in R&D and launching advanced diagnostic solutions that can facilitate early diagnosis and timely intervention in high-risk pregnancies. Development of rapid diagnostic tests and home-use kits can further help expand the market reach in remote locations.

Porter's Analysis

Threat of new entrants: Low barriers to entry due to low capital requirements and technology, however established players dominate the market.

Bargaining power of buyers: Buyers have moderate bargaining power due to availability of substitutes but demand for quick result is driving customers towards established brands.

Bargaining power of suppliers: Suppliers have moderate power due to competitive prices offered by suppliers of raw materials and reagents.

Threat of new substitutes: Substitutes pose medium threat as existing devices and testing methods can be substituted with advanced substitutes.

Competitive rivalry: High due to varying product portfolios, pricing strategies and geographic presence of major players.

SWOT Analysis

Strengths: Growing incidence of preeclampsia and availability of reimbursement and funding for diagnostics.

Weaknesses: Low awareness, lack of widespread adoption of advanced methods in developing regions.

Opportunities: Untapped emerging markets, technological advancements in imaging, biomarkers and point of care testing.

Threats: stringent regulations, pricing pressure from generic manufacturers.

Key Takeaways

The Global Preeclampsia Diagnostics Market Demand is expected to witness high growth due to rising healthcare expenditure and increasing awareness about the condition. The global Preeclampsia Diagnostics Market is estimated to be valued at US$ 1587.53 Mn in 2023 and is expected to exhibit a CAGR of 5.6% over the forecast period 2023 to 2030.

North America currently dominates the market due to presence of advanced healthcare infrastructure and high acceptance of advanced diagnostic methods. However, Asia Pacific is expected to offer lucrative opportunities owing to growing healthcare needs of large population base and increasing investment by market players. These countries offer significant opportunities for players due to presence of untapped demand and progressive shift towards organized healthcare services.

Key players operating in the preeclampsia diagnostics market are AstraZeneca, CorMedix, Inc., Citus Pharmaceuticals, Fresenius Medical Care, Glenmark Pharmaceuticals Ltd., Geistlich Pharma, Merck & Co., Inc., Pfizer, TauroPhar GmbH and Xellia Pharmaceuticals Ltd. These players are focused on new product launches, collaborations and geographic expansion to strengthen their market position.

Get more insights on this topic :

www.pressreleasebulletin.com/preeclampsia-diagnostics-market-propelled-by-increasing-focus-on-early-screening-and-diagnosis/